<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02092298</url>
  </required_header>
  <id_info>
    <org_study_id>2013-0989</org_study_id>
    <secondary_id>NCI-2014-01105</secondary_id>
    <nct_id>NCT02092298</nct_id>
  </id_info>
  <brief_title>Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Metastatic Gastric Cancer</brief_title>
  <official_title>A Phase II Study of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Gastric Carcinomatosis or Positive Cytology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if hyperthermic intraperitoneal&#xD;
      chemotherapy (HIPEC) will help to control the disease in patients with Stage 4 stomach or&#xD;
      gastroesophageal cancer. The safety of this treatment will also be studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIPEC Treatment:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, on the day of HIPEC treatment,&#xD;
      you will receive heated mitomycin-C and cisplatin as a liquid that is injected through 3 to 4&#xD;
      small incisions in your abdomen for about 1 hour. This will be done as a surgical procedure,&#xD;
      and you will be under general anesthesia. The chemotherapy will then be flushed out of your&#xD;
      abdomen and collected, and the treatment area inside your abdomen will be washed. Also during&#xD;
      the HIPEC procedure, fluid will be collected and checked for cancer cells. As is standard of&#xD;
      care, any lesions that are found during treatment may also be biopsied at this time, if the&#xD;
      study doctor thinks it is necessary. You may receive up to 5 HIPEC treatments on this study.&#xD;
&#xD;
      You will also receive sodium thiosulfate by vein over about 20 minutes to protect the&#xD;
      kidneys.&#xD;
&#xD;
      You will remain in the hospital for 3-7 days after treatment.&#xD;
&#xD;
      While you are in the hospital after surgery:&#xD;
&#xD;
        -  Blood (about 2-3 tablespoons) may be drawn for routine tests, if the study doctor thinks&#xD;
           it is necessary.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      One (1) time between Weeks 2-6:&#xD;
&#xD;
        -  You will have a physical exam.&#xD;
&#xD;
        -  Blood (about 2-3 tablespoons) will be drawn for routine tests.&#xD;
&#xD;
      Gastrectomy Surgery:&#xD;
&#xD;
      If your doctor thinks it is needed, you will have a standard of care surgery. You will&#xD;
      receive a separate consent form which explains the surgery and its risks.&#xD;
&#xD;
      On or before 8 weeks after your surgery:&#xD;
&#xD;
        -  You will have a physical exam.&#xD;
&#xD;
        -  Blood (about 2-3 tablespoons) will be drawn for routine tests.&#xD;
&#xD;
      Follow-Up Visits:&#xD;
&#xD;
      You will have routine clinic visits every 6 months from the date of your last surgery. You&#xD;
      will be asked about any other cancer treatments you may be receiving. If you stopped the&#xD;
      study early, the study doctor may ask you to return to the office for extra CT scans, PET&#xD;
      scan, or MRIs during the follow-up period.&#xD;
&#xD;
      You will have a CT scan, PET scan, or MRI of your chest, abdomen, and pelvis every 6 months&#xD;
      for 5 years after surgery to check the status of the disease.&#xD;
&#xD;
      Length of Study Participation:&#xD;
&#xD;
      You will be on study for about 5 years after your last surgery. You will be taken off study&#xD;
      early if the disease gets worse, if intolerable side effects occur, or if you are unable to&#xD;
      follow study directions.&#xD;
&#xD;
      Your participation on the study will be over after the follow-up visits.&#xD;
&#xD;
      This is an investigational study. The chemotherapy and surgery are standard treatment for&#xD;
      stomach and gastroesophageal cancer. It is investigational to give the chemotherapy by HIPEC.&#xD;
&#xD;
      Up to 30 participants will take part in this study. All will be enrolled at MD Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 8, 2014</start_date>
  <completion_date type="Actual">May 12, 2020</completion_date>
  <primary_completion_date type="Actual">May 12, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS) After Hyperthermic Intraperitoneal Chemotherapy</measure>
    <time_frame>Between the second and sixth week after treatment, up to 5 years</time_frame>
    <description>Primary objective of study is to assess overall survival (OS) in subjects with stage IV gastric cancer representing positive cytology or imaging occult carcinomatosis after laparoscopic hyperthermic intraperitoneal chemotherapy administration. Overall survival measured from time of laparoscopic HIPEC. Patterns of tumor recurrence and survival assessed by reviewing routine surveillance CT scans. Overall survival time estimated using the Kaplan-Meier method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS) From the First Laparoscopic HIPEC</measure>
    <time_frame>From the day of surgery, until the last day of follow up, until death, up to 5 years</time_frame>
    <description>Primary objective of study is to assess overall survival (OS) in subjects with stage IV gastric cancer representing positive cytology or imaging occult carcinomatosis after the first laparoscopic HIPEC. Patterns of tumor recurrence and survival assessed by reviewing routine surveillance CT scans. Overall survival time estimated using the Kaplan-Meier method.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Gastrointestinal Cancer</condition>
  <arm_group>
    <arm_group_label>Hyperthermic Intraperitoneal Chemotherapy (HIPEC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laparoscopic HIPEC consists of Mitomycin C 30 mg and Cisplatin 200 mg for 60 minutes, performed 2-8 weeks after completion of systemic chemotherapy. Loading dose Sodium Thiosulfate 7.5 gm/M2 infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by infusion pump over 12 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin C</intervention_name>
    <description>Mitomycin C 30 mg delivered laparoscopically for 60 minutes.</description>
    <arm_group_label>Hyperthermic Intraperitoneal Chemotherapy (HIPEC)</arm_group_label>
    <other_name>Mitomycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 200 mg delivered laparoscopically 60 minutes, 2-8 weeks after completion of systemic chemotherapy.</description>
    <arm_group_label>Hyperthermic Intraperitoneal Chemotherapy (HIPEC)</arm_group_label>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol</other_name>
    <other_name>CDDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Thiosulfate</intervention_name>
    <description>Loading dose of 7.5 gm/M2 of Sodium Thiosulfate infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by continuous infusion pump over 12 hours.</description>
    <arm_group_label>Hyperthermic Intraperitoneal Chemotherapy (HIPEC)</arm_group_label>
    <other_name>Tinver</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years and above. There will be no upper age restriction.&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group (ECOG) performance status &lt;/= 2.&#xD;
&#xD;
          3. Cytologic or histologic proof of adenocarcinoma of the stomach or gastroesophageal&#xD;
             junction.&#xD;
&#xD;
          4. Adequate renal, and bone marrow function: a. Leukocytes &gt;/= 3,000/microL; b. Absolute&#xD;
             neutrophil count &gt;/= 1,500/microL; c. Platelets &gt;/= 100,000/Ul; d. Serum creatinine&#xD;
             &lt;/= 1.5 mg/dL.&#xD;
&#xD;
          5. Hepatic function: AST (SGOT)/ALT (SGPT) &lt;/= 5 X institutional (Upper Limit of Normal)&#xD;
             ULN.&#xD;
&#xD;
          6. Distant Metastatic Disease limited to peritoneum and radiologically occult (not&#xD;
             visualized on preoperative imaging to include [Computerized Tomography] CT scan,&#xD;
             Ultrasound, [Magnetic Resonance Imaging] MRI, PET/CT): a. Positive peritoneal&#xD;
             cytology; b. Carcinomatosis on diagnostic laparoscopy or laparotomy.&#xD;
&#xD;
          7. Completion of preoperative systemic chemotherapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Distant metastatic disease not limited to peritoneum: a. Solid organ metastases&#xD;
             (liver, central nervous system, lung).&#xD;
&#xD;
          2. Any distant metastatic disease visualized on preoperative imaging: a. Solid organ&#xD;
             metastases; b. Clear radiologic evidence of carcinomatosis.&#xD;
&#xD;
          3. Infections such as pneumonia or wound infections that would preclude protocol therapy.&#xD;
&#xD;
          4. Women with a positive urine or serum pregnancy test are excluded from this study;&#xD;
             women of childbearing potential (defined as those who have not undergone a&#xD;
             hysterectomy or who have not been postmenopausal for at least 24 consecutive months)&#xD;
             must agree to refrain from breast feeding and practice adequate contraception as&#xD;
             specified in the informed consent. Adequate contraception consists of oral&#xD;
             contraceptive, implantable contraceptives, injectable contraceptives, a double barrier&#xD;
             method, or abstinence.&#xD;
&#xD;
          5. Subjects with unstable angina or New York Heart Association Grade II or greater&#xD;
             congestive heart failure.&#xD;
&#xD;
          6. Subjects deemed unable to comply with study and/or follow-up procedures.&#xD;
&#xD;
          7. Subjects with a known hypersensitivity to protocol systemic chemotherapy that was&#xD;
             life-threatening, required hospitalization or prolongation of existing&#xD;
             hospitalization, or resulted in persistent or significant disability or incapacity.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian D. Badgwell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 18, 2014</study_first_submitted>
  <study_first_submitted_qc>March 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2014</study_first_posted>
  <results_first_submitted>November 24, 2020</results_first_submitted>
  <results_first_submitted_qc>May 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 15, 2021</results_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastrointestinal cancer</keyword>
  <keyword>Hyperthermic Intraperitoneal Chemoperfusion</keyword>
  <keyword>HIPEC</keyword>
  <keyword>Gastric carcinomatosis</keyword>
  <keyword>Gastroesophageal cancer</keyword>
  <keyword>Mitomycin C</keyword>
  <keyword>Mitomycin</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Platinol-AQ</keyword>
  <keyword>Platinol</keyword>
  <keyword>CDDP</keyword>
  <keyword>Sodium Thiosulfate</keyword>
  <keyword>Tinver</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Hyperthermia</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium thiosulfate</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 19, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT02092298/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: May 2014-July 2016. All recruitment done at The University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>A total of 21 participants were consented, 2 participants were screen failures</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Hyperthermic Intraperitoneal Chemotherapy (HIPEC)</title>
          <description>Laparoscopic HIPEC consists of Mitomycin C 30 mg and Cisplatin 200 mg for 60 minutes, performed 2-8 weeks after completion of systemic chemotherapy. Loading dose Sodium Thiosulfate 7.5 gm/M2 infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by infusion pump over 12 hours.&#xD;
Mitomycin C: Mitomycin C 30 mg delivered laparoscopically for 60 minutes.&#xD;
Cisplatin: Cisplatin 200 mg delivered laparoscopically 60 minutes, 2-8 weeks after completion of systemic chemotherapy.&#xD;
Sodium Thiosulfate: Loading dose of 7.5 gm/M2 of Sodium Thiosulfate infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by continuous infusion pump over 12 hours.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hyperthermic Intraperitoneal Chemotherapy (HIPEC)</title>
          <description>Laparoscopic HIPEC consists of Mitomycin C 30 mg and Cisplatin 200 mg for 60 minutes, performed 2-8 weeks after completion of systemic chemotherapy. Loading dose Sodium Thiosulfate 7.5 gm/M2 infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by infusion pump over 12 hours.&#xD;
Mitomycin C: Mitomycin C 30 mg delivered laparoscopically for 60 minutes.&#xD;
Cisplatin: Cisplatin 200 mg delivered laparoscopically 60 minutes, 2-8 weeks after completion of systemic chemotherapy.&#xD;
Sodium Thiosulfate: Loading dose of 7.5 gm/M2 of Sodium Thiosulfate infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by continuous infusion pump over 12 hours.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" lower_limit="35" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS) After Hyperthermic Intraperitoneal Chemotherapy</title>
        <description>Primary objective of study is to assess overall survival (OS) in subjects with stage IV gastric cancer representing positive cytology or imaging occult carcinomatosis after laparoscopic hyperthermic intraperitoneal chemotherapy administration. Overall survival measured from time of laparoscopic HIPEC. Patterns of tumor recurrence and survival assessed by reviewing routine surveillance CT scans. Overall survival time estimated using the Kaplan-Meier method.</description>
        <time_frame>Between the second and sixth week after treatment, up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hyperthermic Intraperitoneal Chemotherapy (HIPEC)</title>
            <description>Laparoscopic HIPEC consists of Mitomycin C 30 mg and Cisplatin 200 mg for 60 minutes, performed 2-8 weeks after completion of systemic chemotherapy. Loading dose Sodium Thiosulfate 7.5 gm/M2 infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by infusion pump over 12 hours.&#xD;
Mitomycin C: Mitomycin C 30 mg delivered laparoscopically for 60 minutes.&#xD;
Cisplatin: Cisplatin 200 mg delivered laparoscopically 60 minutes, 2-8 weeks after completion of systemic chemotherapy.&#xD;
Sodium Thiosulfate: Loading dose of 7.5 gm/M2 of Sodium Thiosulfate infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by continuous infusion pump over 12 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) After Hyperthermic Intraperitoneal Chemotherapy</title>
          <description>Primary objective of study is to assess overall survival (OS) in subjects with stage IV gastric cancer representing positive cytology or imaging occult carcinomatosis after laparoscopic hyperthermic intraperitoneal chemotherapy administration. Overall survival measured from time of laparoscopic HIPEC. Patterns of tumor recurrence and survival assessed by reviewing routine surveillance CT scans. Overall survival time estimated using the Kaplan-Meier method.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS) From the First Laparoscopic HIPEC</title>
        <description>Primary objective of study is to assess overall survival (OS) in subjects with stage IV gastric cancer representing positive cytology or imaging occult carcinomatosis after the first laparoscopic HIPEC. Patterns of tumor recurrence and survival assessed by reviewing routine surveillance CT scans. Overall survival time estimated using the Kaplan-Meier method.</description>
        <time_frame>From the day of surgery, until the last day of follow up, until death, up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hyperthermic Intraperitoneal Chemotherapy (HIPEC)</title>
            <description>Laparoscopic HIPEC consists of Mitomycin C 30 mg and Cisplatin 200 mg for 60 minutes, performed 2-8 weeks after completion of systemic chemotherapy. Loading dose Sodium Thiosulfate 7.5 gm/M2 infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by infusion pump over 12 hours.&#xD;
Mitomycin C: Mitomycin C 30 mg delivered laparoscopically for 60 minutes.&#xD;
Cisplatin: Cisplatin 200 mg delivered laparoscopically 60 minutes, 2-8 weeks after completion of systemic chemotherapy.&#xD;
Sodium Thiosulfate: Loading dose of 7.5 gm/M2 of Sodium Thiosulfate infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by continuous infusion pump over 12 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) From the First Laparoscopic HIPEC</title>
          <description>Primary objective of study is to assess overall survival (OS) in subjects with stage IV gastric cancer representing positive cytology or imaging occult carcinomatosis after the first laparoscopic HIPEC. Patterns of tumor recurrence and survival assessed by reviewing routine surveillance CT scans. Overall survival time estimated using the Kaplan-Meier method.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious and Other (Not Including Serious Adverse Events) for 30 days and All-Cause Mortality for 5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Hyperthermic Intraperitoneal Chemotherapy (HIPEC)</title>
          <description>Laparoscopic HIPEC consists of Mitomycin C 30 mg and Cisplatin 200 mg for 60 minutes, performed 2-8 weeks after completion of systemic chemotherapy. Loading dose Sodium Thiosulfate 7.5 gm/M2 infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by infusion pump over 12 hours.&#xD;
Mitomycin C: Mitomycin C 30 mg delivered laparoscopically for 60 minutes.&#xD;
Cisplatin: Cisplatin 200 mg delivered laparoscopically 60 minutes, 2-8 weeks after completion of systemic chemotherapy.&#xD;
Sodium Thiosulfate: Loading dose of 7.5 gm/M2 of Sodium Thiosulfate infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by continuous infusion pump over 12 hours.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>Surgical Morbidity</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood Clot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lung Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brian Badgwell,Professor, Surgical Oncology</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>713-745-3715</phone>
      <email>csentonn@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

